‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node mi...

por Rotman, J., Mom, C. H., Jordanova, E. S., de Gruijl, T. D., Kenter, G. G.
Publicado 2018

Expression of endoglin (CD105) in cervical cancer

por Zijlmans, H J, Fleuren, G J, Hazelbag, S, Sier, C F, Dreef, E J, Kenter, G G, Gorter, A
Publicado 2009

Role of IL-12p40 in cervical carcinoma

por Zijlmans, H J M A A, Punt, S, Fleuren, G J, Trimbos, J B, Kenter, G G, Gorter, A
Publicado 2012

HLA-G Expression Is an Independent Predictor for Improved Survival in High Grade Ovarian Carcinomas

por Rutten, M. J., Dijk, F., Savci-Heijink, C. D., Buist, M. R., Kenter, G. G., van de Vijver, M. J., Jordanova, E. S.
Publicado 2014

Efficacy of PD-1 blockade in cervical cancer is related to a CD8(+)FoxP3(+)CD25(+) T-cell subset with operational effector functions despite high immune checkpoint levels

por Heeren, A. M., Rotman, J., Stam, A. G. M., Pocorni, N., Gassama, A. A., Samuels, S., Bleeker, M. C. G., Mom, C. H., Zijlmans, H. J. M. A. A., Kenter, G. G., Jordanova, E. S., de Gruijl, T. D.
Publicado 2019

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients

por van Meir, H., Nout, R. A., Welters, M. J. P., Loof, N. M., de Kam, M. L., van Ham, J. J., Samuels, S., Kenter, G. G., Cohen, A. F., Melief, C. J. M., Burggraaf, J., van Poelgeest, M. I. E., van der Burg, S. H.
Publicado 2016